Quintrio
Home

PHARMACEUTICAL PREPARATIONS

PMGC Holdings Inc. Common Stock

ELAB

PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.47 – $1.74
Volume 139,759
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.94M
Price / earnings
—
Price / book
0.16×
Price / sales
0.4×
EV / sales
-0.67×
EV / EBITDA
0.29×

Profitability

Earnings per share
-$11.38
Return on assets
-9.99%
Return on equity
-109.82%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.65×
Current ratio
1.27×
Quick ratio
1.2×
Cash ratio
1×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ELAB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.53M$1.31M$681.99K$304.14K$285.95K$0$0$0
Cost of revenue$1.93M$920.92K$451.52K$196.85K$207.92K$0$0$0
Gross profit$601.44K$385.69K$230.47K$107.28K$78.03K$0$0$0
Selling, general and administrative$2.53M$2.25M$3.33M$1.53M$1.87M$702.53K$1.1M$974.99K
Research and development$130.26K$310.22K$47.06K$32.9K$15K$66.68K$32.43K$45K
Total operating expenses$3.02M$4.2M$3.55M$2.57M$2.27M$1.01M$1.2M$1.68M
Operating income-$2.42M-$3.82M-$3.32M-$2.47M-$2.19M-$1.01M-$1.2M-$1.68M
Interest expense-$516.49K-$641.23K-$1.04M-$339.77K-$196.88K-$2-$10.47K-$50.62K
Income before taxes-$2.22M-$2.96M-$4.99M-$2.97M-$2.62M-$579.49K-$1.58M-$1.72M
Income taxes$0$0$0$30.97K$0$0$0$0
Net income-$2.24M-$2.94M-$4.97M-$2.98M-$2.59M-$562.36K-$1.61M-$1.93M
Net income attributable to common shareholders-$2.41M-$2.94M-$4.97M-$2.98M-$2.59M-$562.36K-$1.61M-$1.93M
EBITDA-$2.09M-$3.51M-$3.15M-$2.41M-$2.16M-$1.01M-$1.2M-$1.67M
Basic earnings per share-$3.01-$6.03-$111.75-$782.91-$1,178.16-$379.81-$2,480.27-$5,868.96
Diluted earnings per share-$3.01-$6.03-$111.75-$782.91-$1,178.16-$379.81-$2,480.27-$5,868.96

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings

PMGC Holdings Inc. (Nasdaq: ELAB) has executed a payment agreement with Longevity Health Holdings to convert its 5% net sales royalty from the January 2025 Elevai Skincare divestiture into scheduled monthly cash payments through August 2031. The agreement covers the 2025 royalty of $94,937 and all future royalty payments, with installments of $10,000 per month starting October 2026, interest accruing at WSJ Prime plus 1%, and mandatory prepayments triggered by capital events.

GlobeNewswire Inc.

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

PMGC Holdings has entered into a non-binding term sheet with Australia-based Orbit2Orbit to conduct a spaceflight study evaluating NorthStrive Biosciences' muscle-preservation therapeutics (EL-22 and EL-32) in microgravity. The multi-part relationship includes a Mice2Space research collaboration, a U.S. aerospace manufacturing partnership with A&B Aerospace, and a planned CAD $200,000 strategic investment by PMGC in Orbit2Orbit ahead of its proposed Canadian Securities Exchange listing.

GlobeNewswire Inc.

PMGC Holdings Confirms Compliance with Nasdaq’s New $5 Million Market Value of Listed Securities Requirement

PMGC Holdings Inc. (Nasdaq: ELAB) confirmed compliance with Nasdaq's new Market Value of Listed Securities requirement with 8,095,835 shares outstanding as of July 29, 2026. The company is correcting inaccurate share count data from third-party providers and reported significant growth with total assets reaching $26.0 million (up 102% from year-end 2025) and cash of $14.4 million. The company recently completed the acquisition of A&B Aerospace, Inc. in May 2026.

GlobeNewswire Inc.

NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

NorthStrive Biosciences announced plans to initiate an independent flow cytometry (FACS) analysis program to characterize EL-22, an engineered Lactobacillus casei-based therapeutic candidate designed to preserve muscle during weight loss treatments. The study will quantify latent myostatin antigen expression on NorthStrive-manufactured cells and establish comparability against material previously manufactured by MOA Life Plus Co. Ltd., strengthening product identity and manufacturing consistency for future IND-enabling development.

GlobeNewswire Inc.

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences announced positive Phase III results from its AI-driven drug discovery program with Yuva Biosciences. Four small-molecule candidates identified by Yuva's MitoNova™ AI platform demonstrated statistically significant increases in ANT1 protein expression in primary human skeletal muscle cells, with dose-dependent induction ranging from +29% to +50%. The candidates will advance to confirmatory testing in more mature muscle models.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 21, 20261-for-10reverse split
Mar 10, 20261-for-6reverse split
Jan 6, 20261-for-4reverse split
Sep 2, 20251-for-3.5reverse split
Mar 10, 20251-for-7reverse split
Nov 27, 20241-for-200reverse split
Jun 2, 20042-for-1forward split